JAK2 Inhibitor SB1518
Cancer Terms ->
Drugs and Chemicals ->
Pharmacologic Substance ->
Enzyme Inhibitor ->
Protein Kinase Inhibitor ->
Tyrosine Kinase Inhibitor -> JAK2 Inhibitor SB1518
JAK2 Inhibitor SB1518 Definition
An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Oral JAK2 inhibitor SB1518 competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity.
JAK2 Inhibitor SB1518 Synonyms
Oral JAK2 Inhibitor SB1518, SB1518
Terms in JAK2 Inhibitor SB1518 category
Copyright © Cancer Terms 2014 All rights reserved. | Terms of Use | Low Carb Foods
No reproduction or republication permitted.